ASCO 2017 - Relapsed/refractory diffuse large B-cell lymphoma: JCAR017 achieves high CR rates in phase 1 trial

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • At the lower of 2 dose levels (5×107 cells), the response rate was 80% in this phase 1 trial of the second-generation, CD 19-direted, CAR T-cell product JCAR017, with 60% achieving complete response.

Why this matters

  • JCAR017 has significant anticancer activity and a fair safety profile.
  • Multicenter phase 1 trial is still recruiting.

Study design

  • Open-label study to evaluate safety, PK, and antitumor activity of modified T cells (JCAR017) in adult patients with relapsed or refractory B-cell NHL (estimated total enrollment=274).
  • Patients with R/R DLBCL, PMBCL, FL grade 3B, or MCL and adequate organ function are eligible.
  • Treatment: lymphodepletion with fludarabine and cyclophosphamide followed by JCAR017 in a single-dose or 2-dose schedule.
  • Funding: Juno Therapeutics, Inc.

Key results

  • 28 evaluable patients as of November 23, 2016 (25 DLBCL, 2 MCL, 1 FL gra...